A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

Cancer

Volumn 97, Issue 6, 2003, Pages 1442-1446

  Jatoi, Aminah ^a   Ellison, Neil ^b   Burch, Patrick A ^a   Sloan, Jeff A ^a   Dakhil, Shaker R ^c   Novotny, Paul ^b   Tan, Winston ^a   Fitch, Tom R ^a   Rowland, Kendrith M ^d   Young, Charles Y F ^a   Flynn, Patrick J ^e  

^a MAYO CLINIC   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^d Carle Cancer Center Community Clinical Oncology Program   (United States)

^e Metro Minnesota Community Clinical Oncology Program   (United States)

Author keywords

Alternative therapy; Epigallocatechin 3 gallate; Green tea; Polyphenols; Prostate carcinoma; Toxicity

Indexed keywords

CAFFEINE; EPIGALLOCATECHIN GALLATE; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; AGED; ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; FATIGUE; HERBAL MEDICINE; HUMAN; INSOMNIA; MALE; MALE GENITAL TRACT CANCER; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POWDER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE DISEASE; TEA; TREATMENT OUTCOME; VOMITING;

AGED; ANDROGENS; CAMELLIA SINENSIS; CARCINOMA; COMPLEMENTARY THERAPIES; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TEA; TREATMENT OUTCOME;

EID: 0037443797     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11200     Document Type: Article

References (13)

1. Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiologic analysis. J. Urol. 1999;161:1521-1524.
2. Jacobson JS, Chetty AP. Complementary and alternative medicine in prostate cancer. Curr Oncol Rep. 2001;3:448-452.
3. Paschka AG, Butler R, Younf CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett. 1998;130:1-7.
4. Gupta S, Hastak K, Ahmad N, et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA. 2001;98:10350-10355.
5. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med. 1997;26:769-775.
6. Jain MG, Hislop GT, Howe GR, et al. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer. 1998;78:707-711.
7. Heilbrun LK, Nomura A, Stemmermann GN. Black tea consumption and cancer risk: a prospective study. Br J Cancer. 1986;54:677-683.
8. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol. 1999; 17:3461-3467.
9. Pisters KMW, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001;19:1830-1838.
10. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage designs. Biometrics. 1987;43: 81-93.
11. Jankun J, Selman SH, Swierrcz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature. 1997;387: 561.
12. Stoner GD, Mukhtar H. Polyphenols as cancer preventive agents. J Cell Biochem. 1995;22:169-180.
13. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 2002;62:381-385.